Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. More Details
+ 1 more risk
Excellent balance sheet with weak fundamentals.
Share Price & News
How has Wave Life Sciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 1U5's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 1U5 underperformed the German Pharmaceuticals industry which returned 9.8% over the past year.
Return vs Market: 1U5 underperformed the German Market which returned 5.7% over the past year.
Price Volatility Vs. Market
How volatile is Wave Life Sciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Wave Life Sciences undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether Wave Life Sciences is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Wave Life Sciences has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
- Examine Wave Life Sciences's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Wave Life Sciences regulatory filings.
- Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.
How is Wave Life Sciences forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1U5 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 1U5 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 1U5 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 1U5's revenue (4.9% per year) is forecast to grow slower than the German market (6.1% per year).
High Growth Revenue: 1U5's revenue (4.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1U5 is forecast to be unprofitable in 3 years.
How has Wave Life Sciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1U5 is currently unprofitable.
Growing Profit Margin: 1U5 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 1U5 is unprofitable, and losses have increased over the past 5 years at a rate of 40.6% per year.
Accelerating Growth: Unable to compare 1U5's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1U5 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13.2%).
Return on Equity
High ROE: 1U5 has a negative Return on Equity (-5775.98%), as it is currently unprofitable.
How is Wave Life Sciences's financial position?
Financial Position Analysis
Short Term Liabilities: 1U5's short term assets ($146.8M) exceed its short term liabilities ($110.5M).
Long Term Liabilities: 1U5's short term assets ($146.8M) exceed its long term liabilities ($90.1M).
Debt to Equity History and Analysis
Debt Level: 1U5 is debt free.
Reducing Debt: 1U5 had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 1U5 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 1U5 has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 44.9% each year.
What is Wave Life Sciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 1U5's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 1U5's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 1U5's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 1U5's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 1U5's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Paul Bolno (46 yo)
Dr. Paul B. Bolno, M.D., MBA serves as Director at SQZ Biotechnologies Company since July 2020. He has been the Chief Executive Officer and President of WAVE Life Sciences Ltd. since December 2013. Prior t ...
CEO Compensation Analysis
Compensation vs Market: Paul's total compensation ($USD3.58M) is above average for companies of similar size in the German market ($USD1.31M).
Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.
|Chief Technology Officer||0.25yr||US$1.24m||0.040% |
|Chief Medical Officer and Head of Therapeutics Discovery & Development||1.75yrs||US$1.27m||0.048% |
|Interim Chief Financial Officer||0.67yr||no data||0.0059% |
|Senior Vice President of Finance & Operations||3.58yrs||no data||no data|
|Head of Investor Relations||1.42yrs||no data||no data|
|General Counsel||4.33yrs||no data||no data|
|Senior VP of Corporate Development & Head of Emerging Areas||3.67yrs||US$1.68m||0.033% |
|Senior Vice President of Corporate Affairs & Patient Advocacy||0.67yr||no data||no data|
|Senior Vice President of Therapeutics Discovery||0.33yr||no data||no data|
|Director of In Vivo Biology and Ophthalmology||no data||no data||no data|
|Scientific Advisor||3.67yrs||US$29.26k||no data|
Experienced Management: 1U5's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
|Independent Director||1yr||US$259.09k||no data|
|Independent Chairperson||2.92yrs||US$206.11k||0% |
|Independent Director||3.58yrs||US$150.88k||0% |
|Independent Director||5.67yrs||US$151.60k||0% |
|Independent Director||8.17yrs||US$151.33k||0% |
|Independent Director||1yr||US$258.28k||no data|
|Independent Director||1yr||US$258.55k||no data|
|Independent Director||0.083yr||no data||no data|
Experienced Board: 1U5's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.3%.
Wave Life Sciences Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: Wave Life Sciences Ltd.
- Ticker: 1U5
- Exchange: DB
- Founded: 2012
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$712.311m
- Listing Market Cap: US$600.407m
- Shares outstanding: 36.45m
- Website: https://www.wavelifesciences.com
Number of Employees
- Wave Life Sciences Ltd.
- Marina One East Tower
- No. 12-00, 7 Straits View
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|WVE||NasdaqGM (Nasdaq Global Market)||Yes||Ordinary Shares||US||USD||Nov 2015|
|1U5||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Nov 2015|
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The compan ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/20 04:22|
|End of Day Share Price||2020/09/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.